Dasatinib

Catalog No.S1021 Synonyms: BMS-354825

Dasatinib Chemical Structure

Molecular Weight(MW): 488.01

Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 147 In stock
USD 370 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 73 Publications

13 Customer Reviews

  • Antitumor activity (A)and body weight (B) relationship for BLU-285 and dasatinib in a P815 KIT D814Y mastocytoma allograft model.

    Science, 2017, 9(414), doi: 10.1126/scitranslmed.aao1690. Dasatinib purchased from Selleck.

    Combinational treatment of kinase inhibitors induces the similar phenotype produced by PP1. All images are lateral view with dorsal to the top and anterior to the left. The combinational treatment of Dasatinib (D) or U0126 (U) with Sunitinib (SU),PTK787 (PTK), or ZM323881 (Z) resulted in the shrinkage of dorsal aorta.

    Cell Res 2011 21, 1080-1087. Dasatinib purchased from Selleck.

  • Cytotoxicity by Dasatinib and Nutlin-3 used alone or in combination in B-CLL patient leukemic cells. B-CLL patient leukemic cells were exposed to serial doses of Dasatinib or Nutlin- 3 used either alone or in combination, with a fixed ratio, for 48 hours. Dose-effect plots, to determine drug efficacy, are shown for representative B-CLL samples, including 3 patients carrying 17p- (Pt. #7, Pt. #8, and Pt. #10). The decrease of cell viability, labeled "effect" on the Y-axis, was determined in assays done at least twice in duplicate.

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Dasatinib interferes with the p53 transcriptional activity induced by Nutlin-3. Leukemic cell lines were exposed for 24 hours to Dasatinib (10 μM) and Nutlin-3 (10 μM), used either alone or in combination, as indicated. Levels of p53 (A), MDM2 and p21 (B) were assessed by Western blot analysis of total cell lysates. Representative examples of Western blot results are shown. Tubulin staining is shown as loading control; after densitometric analyses, p53 as well as MDM2 and p21 protein levels are expressed as folds of protein modulation, by the indicated treatments, with respect to the control untreated cultures set to 1 (hatched line). *P < 0.05 with respect to the Nutlin-3-treated cultures.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

  • Role of Akt in Dasatinib cytotoxicity and in DasatinibtNutlin-3 synergy. A, whole cell lysates were prepared from EHEB and BJAB cell lines treated (for 16 hours) as indicated, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls (set at 100) on the same membrane. The analysis of modulation of phosphorylation signals for P-ERK1/2, P-p38, and P-Akt are reported (*P < 0.05). Validation of phospho-kinase array results was carried out by Western blot analysis of P-Akt levels.

     

     

    Clin Cancer Res 2011 17, 762-770. Dasatinib purchased from Selleck.

    Impact of the TKI erlotinib, lapatinib, dasatinib, and sorafenib on the viability of MDS/AML cells. MOLM-13 (A) and HL-60 (B) cells were incubated with the indicated doses (given in mM below the x-axis) of the 4 TKI, and cellular viability was assessed by MTT assay after 24, 48 and 72 h of incubation. Changes in viability are given as percentage of cells as compared to non-treated control samples. This experiment was repeated at least three times, yielding comparable results. Graphs show representative results of one experiment carried out in duplicates (mean standard deviation).

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

  • Capacity of the TKI to overcome the AML-typical differentiation blockage. The myeloid cell lines MOLM-13 and HL-60 were incubated for 6 days with 0.01% DMSO (serving as a negative solvent control), 1 μM of ATRA (serving as a positive control), as well as with the indicated doses of the four TKI. (A) Representative May -Gruenwald -Giemsa staining of MOLM-13 cells, (B) quantitation of the percentage of MOLM-13 cells exhibiting at least two morphological signs of differentiation (that is a decrease in cytoplasmic basophilia, a reduction of the nucleo-cytoplasmic ratio, appearance of nuclear lobulation and/or cytoplasmic granules). Percentages were evaluated by examining at least 100 cells/condition; (C) representative FACS overlays of MOLM-13 cells depicting TKI-induced CD11b expression (black line) as compared to the isotype (shaded grey); (D) quantitation of TKI-induced CD11b-expression in MOLM-13 cells; (E) representative slides depicting morphology/staining of MOLM-13 cells assessed in the NBT-reduction assay; (F) respective quantitative assessment demonstrating the NBT-reducing capacity under the different drugs; (G) representative May-Gruenwald-Giemsa staining of HL-60 cells.

     

     

    Biochem Pharmacol 2011 82, 1457-1466. Dasatinib purchased from Selleck.

    Cytotoxicity by Dasatinib treatment in leukemic cells.Leukemic cell lines were exposed to Dasatinib (10 μM). Upon treatment, cell viability (a) was calculated as percentage with respect to the control vehicle cultures (set to 100% for each cell line) and induction of apoptosis (b) was calculated as percentage of Annexin V+/PI+ cells after 48 h of treatment.

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Human phospho-kinase array analysis in response to Dasatinib treatment. Whole cell lysates were prepared from EHEB (p53wt) and BJAB (p53mut) B cell lines, either left untreated or exposed to Dasatinib for 24 h, and hybridized with a human Phospho-Kinase array kit. Spot densities of phospho-proteins were quantified using Image Quant TL software and normalized to those of positive controls on the same membrane. In a, intense decreases of signal of P-p38, PERK1/2 and P-CREB in response to Dasatinib are indicated by arrows in the membranes, and intensity of corresponding spots are reported as graphics. In b, analysis of modulation of phosphorylation of STAT family members in response to Dasatinib (spots not shown). The means±SD of three independent experiments are shown. Asterisk indicates P<0.05 against untreated.

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

    Cells were either left untreated (Unt.) or exposed to Dasatinib (Das.) for 24 h. Equal amounts of cell lysates were analyzed for ERK1/2, p38 and CREB phosphorylation by Western blot using antibodies specific for the native form of the kinases and for residues that are phosphorylated (P-) in each kinase upon activation. One of three experimentswith similar results is shown. Protein bands were quantified by densitometry and level of PERK1/2, P-p38 and P-CREB expressed as arbitrary units,were calculated for each cell line after normalization to total ERK1/2, p38 and CREB respectively

     

     

    Invest New Drugs 2010 30, 417-422. Dasatinib purchased from Selleck.

  • Effect of dasatinib on endothelial cell actin fiber organization. Subconfluent human microvascular endothelial cells‐1 were treated with dimethyl sulfoxide (A) or dasatinib (B), fixed, permeabilized and stained with phalloıdin (green) for F‐actin or FAK (red) for adhesion plaques. Images were taken in a confocal microscope (1000X).

    Cancer Med, 2017, 6(4):809-818. Dasatinib purchased from Selleck.

    Inhibition of cell growth upon culturing of primary bone marrow cells from an EMS patient and a healthy control in presence of TKIs in vitro. EMS cells showed reduced cell growth compared to the healthy control cells when cultured with ponatinib, dovitinb or dasatinib. Cell growth was evaluated after 72 hours in culture. All samples were normalized to DMSO controls. Non-linear regression curves were fitted for evaluation of IC50 values. Error bars represent mean values and standard deviation of the analyzed replicates.

    Eur J Haematol, 2017, 99(5):442-448. Dasatinib purchased from Selleck.

  • Cell vability test result. Different cell lines (A2C12, Beta D5, Gamma A3, Gamma D12, A549, CaCo2,Hep G2) were treated with different concentration of Dasatinib.

     

     

    Dr. Thomas Kruwel of Fraunhofer-Institute for Toxicology and Experimental Medicine-Dasatinib (BMS-354825) purchased from Selleck. Dasatinib purchased from Selleck.

Purity & Quality Control

Choose Selective Src Inhibitors

Biological Activity

Description Dasatinib is a novel, potent and multi-targeted inhibitor that targets Abl, Src and c-Kit, with IC50 of <1 nM, 0.8 nM and 79 nM in cell-free assays, respectively.
Targets
Abl [1]
(Cell-free assay)
Src [1]
(Cell-free assay)
c-Kit (D816V) [2]
(Cell-free assay)
c-Kit (wt) [2]
(Cell-free assay)
0.6 nM 0.8 nM 37 nM 79 nM
In vitro

Dasatinib is more effective than imatinib in inhibiting the proliferation of Ba/F3 cells expressing wild-type Bcr-Abl and Bcr-Abl mutants, with the exception of T315I. Dasatinib has a two-log (∼325-fold) increased potency relative to imatinib. Dasatinib potently inhibits wild-type Abl kinase and all mutants except T315I over a narrow range. Dasatinib directly targets wild-type and mutant Abl kinase domains and inhibits autophosphorylation and substrate phosphorylation in a concentration-dependent manner. Dasatinib displays 325-fold greater potency compared with imatinib against cells expressing wild-type Bcr-Abl. [1] The percent of colonies of TgE bone marrow cells are decreased from 100% in untreated wells to 4.12% in Dasatinib treated wells. In the presence of Dasatinib, the difference in the percentage of colonies formed by WT and TgE bone marrow cells is statistically significant. Expression of LMP2A is able to promote B lymphocyte survival and proliferation, which can be inhibited by targeting Lyn and/or c-Abl kinases through Dasatinib. [3] Dasatinib treatment inhibits Src signaling, decreases growth, and induces cell cycle arrest and apoptosis in a subset of thyroid cancer cells. Treatment with increasing doses of Dasatinib (0.019 μM to 1.25 μM) for 3 days inhibits the growth of the C643, TPC1, BCPAP, and SW1736 cell lines by about 50% at low nanomolar concentrations, while higher concentrations are required to inhibit the growth of the K1 cell line. Treatment with 10 nM or 50 nM Dasatinib results in a 9-22% increase of cells in the G1 population among BCPAP and SW1736 and K1 cells, and a corresponding 7-18% decrease in the percentage of cells in the S phase. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
M07ep210 NVrxfoE3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWrjNngyPzJiaB?= MlK2SG1UVw>? MXPJR|UxRTBwMECwNFch|ryP NWXPcpRzOTd7NU[wPFA>
K562 MnvDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\CWlA4OiCq NETtc5dFVVOR Mn;XTWM2OD1yLkCwNUDPxE1? M3G2WlE4QTV4MEiw
M07e NXXydpNMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPqZYg4OiCq MYjEUXNQ NXTUR5Y1UUN3ME2wMlAxOTJizszN MmTVNVc6PTZyOEC=
ALL3 NWPiellzS3m2b4TvfIlkKEG|c3H5 NHrjVHIxNjIQvF2= NUmw[nlDPzJiaB?= MmD3SG1UVw>? M3fkNWlEPTB;MD6wNFA1KM7:TR?= NFHwfGUyQTh6OUW0NC=>
CML MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3JNlAhdWmw MmjNSG1UVw>? MkPUTWM2OD1yLkCwNUDPxE1? M1XXe|E6OjF7MEG2
BA/F3 M1e1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVO3NkBp M{PxOGROW09? NYS2PId5UUN3ME22MlU5QSEQvF2= MnW2NlMxQDh4NES=
BA/F3 M4rRNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVnJfI9YPzJiaB?= MWnEUXNQ NEDMRlhKdmS3Y3XzJIFvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgcY92e2ViQlGvSlMh[2WubIOg[ZhxemW|c3nu[{BD[3JvQXLsJG0{PTGWIH31eIFvfCC5aYToJGlEPTBib3[gNE4xODB6M988US=> NVjK[INNOjNyOEi2OFQ>
BA/F3 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVe3NkBp MWDEUXNQ MXjJcoR2[2W|IHHueIlxem:uaX\ldoF1cX[nIHHjeIl3cXS7IHHnZYlve3RibX;1d4UhSkFxRkOgZ4VtdHNiZYjwdoV{e2mwZzD3bYxlKHS7cHWgRoNzNUGkbDD3bZRpKEmFNUCgc4YhOC5yMES1{txO MYeyN|A5QDZ2NB?=
BA/F3 NFH3UVBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFzTe484OiCq NVyydIs5TE2VTx?= M{jQTmlv\HWlZYOgZY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6|dDDtc5V{\SCEQT;GN{Bk\WyuczDlfJBz\XO|aX7nJGJkei2DYnygWFMyPUlibYX0ZY51KHerdHigTWM2OCCxZjCxMlcyPM7:TR?= M1ftXFI{ODh6NkS0
BA/F3 NHvRSYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\1[|czKGh? M{fES2ROW09? Ml7xTY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTjR6NmOgcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNFnPxE1? NHf4[2ozOzNyMUewNy=>
BA/F3 NEjqRoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV:xbng3PzJiaB?= NI\zbG9FVVOR M3TuOWlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEV{NUXLJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFMz|ryP MlrHNlM{ODF5MEO=
BA/F3 NHPhdGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWO3NkBp MYjEUXNQ M{nTN2lv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKEd{NUDFJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMD6wNFUy|ryP MUCyN|MxOTdyMx?=
BA/F3 NEnBdWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mli4O|IhcA>? MoK2SG1UVw>? NFe1dJFKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5NqdmdiQlPSMWFDVCCTMkWyTEBufXSjboSgZZN{\XO|ZXSgZZMh\3Kxd4ToJGlvcGmkaYTpc44hf2m2aDDJR|UxKG:oIECuNFA5|ryP M2n3XVI{OzBzN{Cz
BA/F3 NHvMSFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXe3NkBp M1;ocGROW09? MmX1TY5lfWOnczDjfZRwfG:6aXPpeJkh[WejaX7zeEBud3W|ZTDCRU9HOyClZXzsd{BmgHC{ZYPzbY5oKEKFUj3BRmwhTTN3OW[gcZV1[W62IHHzd4V{e2WmIHHzJIdzd3e2aDDJcohq[mm2aX;uJJdqfGhiSVO1NEBw\iByLkCwNVPPxE1? MWGyN|MxOTdyMx?=
BA/F3 NHfOTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnj5O|IhcA>? NVfNSHd1TE2VTx?= NGXKSoRKdmS3Y3XzJIN6fG:2b4jpZ4l1gSCjZ3HpcpN1KG2xdYPlJGJCN0Z|IHPlcIx{KGW6cILld5Nqdmdid3ns[EB1gXCnIFLDVk1CSkxiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECxPe69VQ>? M4PmXVI{OzBzN{Cz
BA/F3 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jWcVczKGh? MlfKSG1UVw>? MWHJcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIV5eHKnc4PpcochSkOULVHCUEB[OjV|SDDteZRidnRiYYPz[ZN{\WRiYYOg[5Jwf3SqIFnubIljcXSrb36ge4l1cCCLQ{WwJI9nKDBwMECyN:69VQ>? M1rMcVI{OzBzN{Cz
BA/F3 NETjTWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX23NkBp NIHYVWdFVVOR M2XPcmlv\HWlZYOgZ5l1d3SxeHnjbZR6KGGpYXnud5QhdW:3c3WgRmEwTjNiY3XscJMh\XiycnXzd4lv\yCEQ2KtRWJNKFR|MUXJJI12fGGwdDDhd5Nme3OnZDDhd{Boem:5dHigTY5pcWKrdHnvckB4cXSqIFnDOVAhd2ZiMz62{txO Mnf0NlM{ODF5MEO=
BA/F3 MkPkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NG\UUmg4OiCq NEC2eFRFVVOR MY\JcoR2[2W|IHP5eI91d3irY3n0fUBi\2GrboP0JI1wfXOnIFLBM2Y{KGOnbHzzJIF{e2W|c3XkJIF{KGe{b4f0bEBKdmirYnn0bY9vKHerdHigTWM2OCCxZjCyMlXPxE1? M1jaVFI{OzBzN{Cz
T cell NG[zUHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIL5S3c4OiCq M2KwcGROW09? NFT3TGFKdmirYnn0d{BidnSrIFPEN{0h[W6mIHHueIkhS0R{OD3pcoR2[2WmIGSgZ4VtdCCycn;sbYZmemG2aX;uJJdqfGhiSVO1NEBw\iByLkCwN:69VQ>? MYWxO|E2PDVzMh?=
WiDr NEPtW|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDCO|IhcA>? MmLqSG1UVw>? MUHJR|UxRTBwMEWyJO69VQ>? Mn7lNVU3OTV3MUK=
PC3 NUC2THNQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPheZJ2PzJiaB?= NV2yWpk6TE2VTx?= MXvJR|UxRTBwMEC5OEDPxE1? MmPSNVU3OTV3MUK=
MDA-MB-231 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnvnO|IhcA>? NEnYVWxFVVOR Ml\LTWM2OD1yLkCxNkDPxE1? NILD[GEyPTZzNUWxNi=>
Hs578T M3H1XWN6fG:2b4jpZ{BCe3OjeR?= Mn\JO|IhcA>? NITIZoZFVVOR MULHTVUxRTBwMEOg{txO NHT2dJkzPDBzNUOyOy=>
HMEC M2DUSmN6fG:2b4jpZ{BCe3OjeR?= M1K1ZVczKGh? MYrEUXNQ NXnI[5pIT0l3ME2xMlgh|ryP MoK3NlQxOTV|Mke=
DU145 M2PyW2N6fG:2b4jpZ{BCe3OjeR?= MljPO|IhcA>? NILTXFRFVVOR NFG2ZVBIUTVyPUCuNVYh|ryP M2X5PFI1ODF3M{K3
U251 NFXwN5ZEgXSxdH;4bYMhSXO|YYm= NInmOYs4OiCq NX:xU44yTE2VTx?= NEnTOW1IUTVyPUKuPFEh|ryP NXTFVFFYOjRyMUWzNlc>
NCI60 M4rC[mN6fG:2b4jpZ{BCe3OjeR?= M1K2c|czKGh? NVrNUGhqTE2VTx?= M1\VW2dKPTB;NT63JO69VQ>? M12yNlI1ODF3M{K3
MALME-3M MULDfZRwfG:6aXOgRZN{[Xl? MlTTO|IhcA>? NGqxN2NFVVOR M4XSemdKPTB;Nj62NUDPxE1? MUSyOFAyPTN{Nx?=
KM12 MXHDfZRwfG:6aXOgRZN{[Xl? MlXmO|IhcA>? MXXEUXNQ M1\IZWdKPTB;Nz60OEDPxE1? MWOyOFAyPTN{Nx?=
SW620 NXqwO3NLS3m2b4TvfIlkKEG|c3H5 MWG3NkBp NF:0bYVFVVOR MV7HTVUxRThwNEOg{txO Mne1NlQxOTV|Mke=
RXF 393NL NVrzWYViS3m2b4TvfIlkKEG|c3H5 NGXsTpE1KGSjeYO= MnzTSG1UVw>? M1rGPGlEPTB;MD6wNlE4KM7:TR?= MVuyN|I2OzB5NB?=
LXFA 983L NFH2R3BEgXSxdH;4bYMhSXO|YYm= MUS0JIRigXN? NES2UohFVVOR MYDJR|UxRTBwMEW2OUDPxE1? M4HScFI{OjV|MEe0
PRXF DU145 MXfDfZRwfG:6aXOgRZN{[Xl? NHGwXng1KGSjeYO= NWjEcWZ{TE2VTx?= NFuyWG1KSzVyPUCuNFYzOyEQvF2= NFrBNmMzOzJ3M{C3OC=>
PAXF 1657L MUHDfZRwfG:6aXOgRZN{[Xl? MoHhOEBl[Xm| MWjEUXNQ M3PNTWlEPTB;MD6xNlEh|ryP MXeyN|I2OzB5NB?=
CXF 1103L MnTjR5l1d3SxeHnjJGF{e2G7 MYK0JIRigXN? NGD5SGVFVVOR NWHzSmdQUUN3ME20MlM3KM7:TR?= MWKyN|I2OzB5NB?=
GXF251L NFjXN4REgXSxdH;4bYMhSXO|YYm= NIWxNlQ1KGSjeYO= Mn[3SG1UVw>? NHrNVoxKSzVyPUKuNlUh|ryP M4LSPVI{OjV|MEe0
NCI-H23 NYLoVXR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1:2TFczKGh? NFzaeJBFVVOR NV;0VXpWUUN3ME2yMlI4KM7:TR?= NH\DR|UzOzV{MUCyNC=>
HCT116 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX23NkBp Mn;FSG1UVw>? MX3JR|UxRTJwMzFOwG0> NID5d5UzOzV{MUCyNC=>
MCF7 MnXKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDVeHk4OiCq MmntSG1UVw>? M4TwW2lEPTB;Mj61O{DPxE1? MmTFNlM2OjFyMkC=
NCI-H460 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEH2NWw4OiCq NIe5eoJFVVOR M2jTPGlEPTB;OD65PUDPxE1? NXnRXpdROjN3MkGwNlA>
DLD1 M2\YNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEH5dpY4OiCq MVLEUXNQ M1zOfWlEPTB;ND62JO69VQ>? NFjzW2gzOzV4N{m2NC=>
NCI-H661 NGTmdoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzlO|IhcA>? M3n2ZmROW09? MmHETWM2OD15Lkig{txO NHHVOHAzOzV4N{m2NC=>
A549 NWrrWZVKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjoPG9nPzJiaB?= MVLEUXNQ NHPFNlVKSzVyPUiuNkDPxE1? NV[0cGRmOjN3Nke5OlA>
U937 NGLFRlJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVe3NkBp MkLWSG1UVw>? MY\JR|UxRTF{LkKg{txO MlTGNlM2Pjd7NkC=
HEK293 MlnSSpVv[3Srb36gRZN{[Xl? M3TTflExyqEQvF2= MnfsSG1UVw>? M3PmNWlv\HWlZYOgZolv\GmwZzDh[oZqdmm2eTD0c{BpfW2jbjDmeYxtNWynbnf0bEBJcXNvdHHn[4VlKE27dEGgb4lv[XOnIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODZ|zszN MXWyNlc4ODZzMB?=
HUVEC M2TxT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jaSFAvOTYEoN88US=> M2Lw[|czKGh? MYjEUXNQ NVvlbIFXUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDj[YxtKGe{b4f0bEBifCByLkG1JJVO NFy4fHUzOjh3M{m5Ny=>
HUVEC NEfjUVJHfW6ldHnvckBCe3OjeR?= MoXONVXDqM7:TR?= NFW5ToI4OiCq MVLEUXNQ NXywOo5YUW6mdXPld{BidnSrYX7nbY9o\W6rYzDhZ5Rqfmm2eTDpckBJXV[HQzDjc{1kfWy2dYLl[EB4cXSqII\hd4N2dGG{IIPtc491cCCvdYPjcIUh[2WubIOgZZN{\XO|ZXSgZZMhUW6qaXLpeIlwdiCxZjDu[ZR4d3KtIH\vdo1ifGmxbjDheEAyNjhidH:gNVUhfU1? M1XoNFIzQDV|OUmz
Plasmodium falciparum MXLGeY5kfGmxbjDBd5NigQ>? M4\vblExyqEQvF2= NXrlcIR1OTVibXnu NYLDfFhQTE2VTx?= M17tXmlvcGmkaYTzJHBt[XOvb3TpeY0h\mGuY3nwZZJ2dSCycn;sbYZmemG2aX;uJIJ6KGmwaHnibZRqdmdidHjlJGZ2dmO2aX;uJI9nKFCoQ1TQT|EheHKxdHXpckB4cXSqIFnDOVAhd2ZiMT6xO:69VQ>? MYOyOFU2ODN|MB?=
PC3 M4DENGZ2dmO2aX;uJGF{e2G7 M{jBclAvOSEQvF2= M4TjOFUhcA>? MUXEUXNQ NV;yNnpSUW6qaXLpeJMhcHWvYX6gVGM{KGOnbHygZYRp\XOrb36gZZQhOTByIH7N NYSxV2tqOTl2NkK5O|U>
DU145 M4TpPWZ2dmO2aX;uJGF{e2G7 MlHINE4yKM7:TR?= MojMOUBp MmP5SG1UVw>? MnjaTY5pcWKrdIOgbJVu[W5iRGWxOFUh[2WubDDh[Ihme2mxbjDheEAyODBibl2= M4CyUVE6PDZ{OUe1
PC3 NYnSdmdXU2mwYYPlJGF{e2G7 NUG5NmxCOC5zIN88US=> NHHJeWU2KGh? MU\EUXNQ MlzuTY5pcWKrdIOgZ3Nz[yCrbjDoeY1idiCSQ{OgZ4VtdHNiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKHCqb4PwbI9zgWyjdHXkJHNz[yC\NEG2JIxmfmWuIHH0JFExOCCwTR?= Ml6wNVk1PjJ7N{W=
DU145 M{fMcWtqdmG|ZTDBd5NigQ>? Mn\1NE4yKM7:TR?= NFjmWWk2KGh? NYDZZVRFTE2VTx?= NYLMWHFqUW6qaXLpeJMh[1O{YzDpckBpfW2jbjDEWVE1PSClZXzsd{Bie3Onc4Pl[EBieyC{ZXT1Z5Rqd25ib3[gdIhwe3Cqb4L5cIF1\WRiU4LjJHk1OTZibHX2[Ywh[XRiMUCwJI5O NX22SJRFOTl2NkK5O|U>
PC3 MXrLbY5ie2ViQYPzZZk> NEPoVoExNjFizszN Ml3mOUBp Mn\jSG1UVw>? NIfENWZKdmirYnn0d{BkW3KlIHnuJIh2dWGwIGDDN{Bk\WyuczDhd5Nme3OnZDDhd{Bz\WS3Y4Tpc44hd2ZicHjvd5Bpd3K7bHH0[YQhTkGNIGm1O|YwYTV5NzDs[ZZmdCCjdDCxNFAhdk1? NEPOVpoyQTR4Mkm3OS=>
DU145 NYfnO3VQU2mwYYPlJGF{e2G7 NWWxXYJ6OC5zIN88US=> MnuzOUBp M1rCS2ROW09? M3jPSGlvcGmkaYTzJINUemNiaX6gbJVu[W5iRGWxOFUh[2WubIOgZZN{\XO|ZXSgZZMhemWmdXP0bY9vKG:oIIDoc5NxcG:{eXzheIVlKE[DSzDZOVc3N1l3N{egcIV3\WxiYYSgNVAxKG6P NES4VVUyQTR4Mkm3OS=>
Huh7 M2nPT2FvfGm4aYLhcEBCe3OjeR?= NWj1T5VQOi53IN88US=> NXr4fllyPCCmYYnz NXfJS5h2TE2VTx?= NF;NTmFKdmirYnn0d{B3cXKjbDDzdJJm[WRiaX6gSIVv\3WnII\pdpV{NWmwZnXjeIVlKGi3bXHuJGh2cDdiY3XscJMh[XO|ZYPz[YQh[XNiYXPjeY12dGG2aX;uJI9nKH[rcnHsJIVvfmWub4DlJJBzd3SnaX6ge4l1cGmwIIDldolvfWOuZXHyJJJm\2mxbjDheEAzNjVidV2= M1vaW|E4OzZyNke2
C6/36 Mnf5RY51cX[rcnHsJGF{e2G7 MV2yMlUh|ryP NXPhfZF2PCCmYYnz NX35eW9QTE2VTx?= NWDMU5hjUW6qaXLpeJMhfmm{YXygd5Bz\WGmIHnuJGRmdme3ZTD2bZJ2ey2rbn\lZ5Rm\CCjc3nhckB1cWencjDtc5NyfWm2bzDDOk8{PiClZXzsd{Bie3Onc4Pl[EBieyCjY3P1cZVt[XSrb36gc4Yhfmm{YXyg[Y53\WyxcHWgdJJwfGWrbjD3bZRpcW5icHXybY52[2ynYYKgdoVocW:wIHH0JFIvPSC3TR?= MmrENVc{PjB4N{[=
U937 M36xNWZ2dmO2aX;uJGF{e2G7 MVmxJO69VQ>? NGryN5YyKGh? MlzUSG1UVw>? MYPS[YR2[2W|IHLhd4FtKFSQRnHsdIhiKHKnbHXhd4UhcW5iaIXtZY4hXTl|NzDj[Yxtew>? MkjJNVc3QDRyOUm=
U937 M4LmR2Z2dmO2aX;uJGF{e2G7 NFXlbXEyKM7:TR?= MmLZNUBp Mk\sSG1UVw>? MknDVoVlfWOnczDMVHMucW6mdXPl[EBVVk[jbIDoZUBz\WynYYPlJIlvKGi3bXHuJHU6OzdiY3XscJM> MWWxO|Y5PDB7OR?=
murine mast cell MmXrSpVv[3Srb36gRZN{[Xl? MmLUNUDPxE1? Moq3NlQhcA>? MlzpSG1UVw>? MXvJcohq[mm2czDhcpRq\2WwLXnu[JVk\WRiSVy2JJNm[3KndHnvckBqdiCLZ1WgdJJqdWWmIH3veZNmKG2jc4SgZ4VtdHNiYYSgNUB2VQ>? M3vTWVE4Pjh2MEm5
BV-173 NVP0N|VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnVTWM2OD1yLkCwNFAxODFyOTFOwG0> MXjTRW5ITVJ?
K-562 NFnC[4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHk[GJIUUN3ME2wMlAxODByMEK2OkDPxE1? NFPCcmZUSU6JRWK=
BL-70 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLjd|N4UUN3ME2wMlAxODByMEiyNkDPxE1? M{nmdHNCVkeHUh?=
EM-2 NYDaXnpwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGTHb21KSzVyPUCuNFAxODBzMEig{txO NH7LbXNUSU6JRWK=
LAMA-84 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M33GdWlEPTB;MD6wNFAxODN{MTFOwG0> NWTHT3BXW0GQR1XS
MEG-01 NVfRNZB2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2m3bGlEPTB;MD6wNFAxODl6IN88US=> NIjMNHNUSU6JRWK=
EoL-1-cell MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn7QTWM2OD1yLkCwNFAyOzFizszN M4jzTXNCVkeHUh?=
CTV-1 M3TtO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{H5cWlEPTB;MD6wNFAxPDB2IN88US=> Ml\HV2FPT0WU
TE-15 NXXJb29IT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fUc2lEPTB;MD6wNFU5QSEQvF2= NGLCUlFUSU6JRWK=
NOS-1 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlrpTWM2OD1yLkCwOlE{KM7:TR?= Mo\vV2FPT0WU
D-336MG NInGZmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml22TWM2OD1yLkCwOlMh|ryP NI\Tc2NUSU6JRWK=
LB1047-RCC MoCwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmHWTWM2OD1yLkCwPVg6KM7:TR?= M3;KdHNCVkeHUh?=
LB996-RCC NXjtNoJnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwMEC5PVEh|ryP M1\a[HNCVkeHUh?=
SW982 M1X4PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwMEGxNVUh|ryP M125dHNCVkeHUh?=
TK10 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kN3RKSzVyPUCuNFEyPzRizszN NIrX[GlUSU6JRWK=
A704 NWrmZlhFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjPOYlKSzVyPUCuNFE1QTFizszN NEi5VlJUSU6JRWK=
TE-8 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2jKS2lEPTB;MD6wNVU4PiEQvF2= M4qyVXNCVkeHUh?=
DOHH-2 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlz3TWM2OD1yLkCxO|E6KM7:TR?= MUXTRW5ITVJ?
HOP-62 NIDkcVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXfUOHl{UUN3ME2wMlAyQDN2IN88US=> M{PFUXNCVkeHUh?=
TE-12 NVX3PJBmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETHXWVKSzVyPUCuNFE5PjFizszN NHjF[npUSU6JRWK=
KGN MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3:2[GlEPTB;MD6wNVk1OiEQvF2= M2LrdHNCVkeHUh?=
NCI-H1648 NXT2SHI{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIXQUIJKSzVyPUCuNFIxOTFizszN M2HOSHNCVkeHUh?=
OS-RC-2 M4T0fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{D5XGlEPTB;MD6wNlA{KM7:TR?= MlT6V2FPT0WU
GB-1 NITnZ2ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX;JR|UxRTBwMEKxOVch|ryP NFTOZlhUSU6JRWK=
RXF393 NHzvbJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlrITWM2OD1yLkCyN|U4KM7:TR?= MoCxV2FPT0WU
LC-2-ad NVzhTIRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\T[G9KSzVyPUCuNFI2QDZizszN NUCx[olZW0GQR1XS
KS-1 MoO4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTUTWM2OD1yLkCyO|Mh|ryP NXf2N3NuW0GQR1XS
ETK-1 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHz5c3dKSzVyPUCuNFI5OzJizszN MUXTRW5ITVJ?
SW954 NYOy[|N{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfH[212UUN3ME2wMlAzQTJ5IN88US=> MoruV2FPT0WU
Becker NEPKS2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMEOwNFMh|ryP M3;Od3NCVkeHUh?=
MZ1-PC M2TSNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnLTTWM2OD1yLkCzNVE6KM7:TR?= M3PkR3NCVkeHUh?=
ES6 NIL1eoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGT1VYtKSzVyPUCuNFMyQTNizszN MknkV2FPT0WU
KURAMOCHI M1TLW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUDCfXZsUUN3ME2wMlA{PDh5IN88US=> M2rnXnNCVkeHUh?=
CGTH-W-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXPJR|UxRTBwMEO1OFgh|ryP M3\OenNCVkeHUh?=
VA-ES-BJ MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMEO5NFIh|ryP MXTTRW5ITVJ?
LXF-289 M{DXeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO5TWM2OD1yLkCzPVU3KM7:TR?= NUjkd45qW0GQR1XS
MPP-89 M2T1W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2GzPWlEPTB;MD6wOFA1QSEQvF2= NVzQdpdKW0GQR1XS
SW872 NFr5NY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Moi4TWM2OD1yLkC0NVYyKM7:TR?= MUPTRW5ITVJ?
SNB75 M2HaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoCwTWM2OD1yLkC0OFM2KM7:TR?= NXrmcWc5W0GQR1XS
PSN1 Mmj2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMES0O|Qh|ryP NFf0blNUSU6JRWK=
LB831-BLC M4Xkcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTBwMES2NFkh|ryP NVfxR3NnW0GQR1XS
MFH-ino M2D4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfsOW1KSzVyPUCuNFQ4OjRizszN MYjTRW5ITVJ?
TGBC24TKB NYnlXm1jT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TMdmlEPTB;MD6wOFc3OSEQvF2= MoO2V2FPT0WU
A388 M3f2fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1vVT2lEPTB;MD6wOVA6PSEQvF2= M2rKRnNCVkeHUh?=
BB30-HNC MkPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlixTWM2OD1yLkC1OFM4KM7:TR?= NVnDN|FsW0GQR1XS
GI-ME-N M4nrVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnsUoZwUUN3ME2wMlA3OTF6IN88US=> MWPTRW5ITVJ?
TGBC1TKB M2rqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYP0[mlXUUN3ME2wMlA3OTZ2IN88US=> NV3hOWx6W0GQR1XS
TE-10 MnzjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkjJTWM2OD1yLkC2N|U4KM7:TR?= MWXTRW5ITVJ?
A498 NU\Nc2l5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXL5d5BHUUN3ME2wMlA4Ojh2IN88US=> MkjVV2FPT0WU
TE-11 NG\nW3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnzwTWM2OD1yLkC3PFU5KM7:TR?= M2jJOXNCVkeHUh?=
BB65-RCC NUn6RYNTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUC4c2VyUUN3ME2wMlA5OjJ5IN88US=> MorpV2FPT0WU
C2BBe1 NF:yNpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXnJR|UxRTBwMEizNFgh|ryP MWDTRW5ITVJ?
NCI-H747 NFHtNFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{XkSmlEPTB;MD6wPFM3OiEQvF2= MXXTRW5ITVJ?
IST-MES1 NGnZU|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;sbJZKSzVyPUCuNFg2PTJizszN MX;TRW5ITVJ?
KALS-1 NWizOW0{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVq1XpFHUUN3ME2wMlA6PDlizszN MmDWV2FPT0WU
GCIY MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH62UYhKSzVyPUCuNFk3PTZizszN NFj4TIJUSU6JRWK=
RL95-2 NEX4WXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7oTWM2OD1yLkGwN|gh|ryP MXXTRW5ITVJ?
TE-1 Mk\6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mme1TWM2OD1yLkGwOVQh|ryP NFyyXYFUSU6JRWK=
NCI-H1355 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILRfZJKSzVyPUCuNVExOjhizszN MlXtV2FPT0WU
SW962 NELlVWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnHKTWM2OD1yLkGxNlkzKM7:TR?= NXXRcnpFW0GQR1XS
KLE NESw[VFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjTfIhKSzVyPUCuNVE{OTdizszN NVPPcJhbW0GQR1XS
MC116 Mmj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlTTTWM2OD1yLkGxOFEh|ryP MoXhV2FPT0WU
NMC-G1 MnS1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HGSmlEPTB;MD6xNVYxPiEQvF2= MVjTRW5ITVJ?
KU812 NVvMOYdsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWDUemtJUUN3ME2wMlEyQDh|IN88US=> MlrNV2FPT0WU
COLO-829 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlTJTWM2OD1yLkGyNlE{KM7:TR?= NIXPbYpUSU6JRWK=
NTERA-S-cl-D1 NULT[HN6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHjOJRKSzVyPUCuNVIzQDNizszN MmTZV2FPT0WU
IST-MEL1 M3\QVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVLuSmVvUUN3ME2wMlE{PDVizszN NUTQWGgyW0GQR1XS
MLMA MknpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzEeHhsUUN3ME2wMlE1ODN{IN88US=> NESzR5RUSU6JRWK=
LS-123 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7Z[XJKSzVyPUCuNVQxPjRizszN NGjNfXpUSU6JRWK=
LB2518-MEL NI\hb|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\FXo1MUUN3ME2wMlE1OTZ{IN88US=> NHXue2pUSU6JRWK=
NB69 M321fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlTzTWM2OD1yLkG0OFM3KM7:TR?= Mmj1V2FPT0WU
8-MG-BA M{nvOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zOeGlEPTB;MD6xOVQ2QCEQvF2= M3rvOnNCVkeHUh?=
K5 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXH3WGhqUUN3ME2wMlE3PDh7IN88US=> NIDxPZVUSU6JRWK=
KINGS-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3X2RmlEPTB;MD6xOlY3PiEQvF2= NET5TlRUSU6JRWK=
SF268 MkCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXTJR|UxRTBwMUe0NFQh|ryP MmTqV2FPT0WU
PF-382 M4jmSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvwUJJKSzVyPUCuNVc3PzhizszN Ml3sV2FPT0WU
SH-4 NY\kfpZ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;LSmlEPTB;MD6xPFQyOyEQvF2= NVzjWGZZW0GQR1XS
NALM-6 M{jRRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HWS2lEPTB;MD6xPVI6PSEQvF2= M321Z3NCVkeHUh?=
CP66-MEL NXjOXmdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTBwMUm1N|Eh|ryP NGDidodUSU6JRWK=
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWHSW25yUUN3ME2wMlE6QTh5IN88US=> MlTCV2FPT0WU
CP67-MEL M{TpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1mzSmlEPTB;MD6yNFQ5QCEQvF2= NYD2WWhYW0GQR1XS
DSH1 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX3JR|UxRTBwMkSwNFEh|ryP M2DoNXNCVkeHUh?=
HCE-4 MlfwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3ji[GlEPTB;MD6yOlQ{QSEQvF2= NEjZWI5USU6JRWK=
MZ2-MEL NFL5PIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMki1N|ch|ryP MnfnV2FPT0WU
BL-41 M3;u[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;0VmlEPTB;MD6yPVEzOyEQvF2= M1HhRnNCVkeHUh?=
HUTU-80 NWjkOINDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoG3TWM2OD1yLkOxOFIh|ryP M3\2e3NCVkeHUh?=
LOXIMVI NYD2OYJMT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\NOGlEPTB;MD6zNVUxOyEQvF2= MVzTRW5ITVJ?
no-10 NU\wUpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPkNm84UUN3ME2wMlMyQTNzIN88US=> NVrmbFNvW0GQR1XS
KARPAS-422 MlnoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4O5e2lEPTB;MD6zN|k6PyEQvF2= M3z0dnNCVkeHUh?=
SW684 MoT3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33YSGlEPTB;MD6zOFk5KM7:TR?= NISzSVNUSU6JRWK=
SF126 NHTBXllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{DYUGlEPTB;MD6zOVQyKM7:TR?= MnPBV2FPT0WU
D-263MG M1HNOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\tTWM2OD1yLkO2NlI1KM7:TR?= M2L5c3NCVkeHUh?=
OVCAR-4 MnjZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDmUYhKSzVyPUCuN|c1OzNizszN NE\XcXhUSU6JRWK=
BB49-HNC NE\ie4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHHXe3VKSzVyPUCuN|g2QTlizszN NHu5V|NUSU6JRWK=
ONS-76 NXrtbVd[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;FWY1kUUN3ME2wMlQzQTVzIN88US=> MVHTRW5ITVJ?
MZ7-mel MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4nsS2lEPTB;MD60O|kyOSEQvF2= NX\5fY1pW0GQR1XS
RCC10RGB M2jWe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUHJR|UxRTBwNEmxNUDPxE1? M3;QUnNCVkeHUh?=
BOKU M1HxbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXLJR|UxRTBwNEmxN|Mh|ryP NGDWW4hUSU6JRWK=
no-11 MmjOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGjacXZKSzVyPUCuOVAzOjhizszN NGi3[2RUSU6JRWK=
IST-SL2 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTBwNUCzNFIh|ryP MXPTRW5ITVJ?
RKO M3nxWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7o[YRnUUN3ME2wMlUzQTZ4IN88US=> MWDTRW5ITVJ?
HT-144 M2n5[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NW[5T4JkUUN3ME2wMlU{PjB7IN88US=> NHzWfGdUSU6JRWK=
NCI-H446 MmHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrVTWM2OD1yLk[yO|Yh|ryP NVLObVE2W0GQR1XS
QIMR-WIL MorxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTBwN{C2Nlkh|ryP M1HPOnNCVkeHUh?=
MHH-PREB-1 M3iwdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTBwN{S0Olkh|ryP NV2zeIpIW0GQR1XS
EW-16 M1PQXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1Tlb2lEPTB;MD63OlE4QCEQvF2= M4P4fXNCVkeHUh?=
EW-24 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFnZWFhKSzVyPUCuO|gyPjVizszN NFvjbY5USU6JRWK=
LB373-MEL-D NIOwd3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlW2TWM2OD1yLkiyOVA5KM7:TR?= MXHTRW5ITVJ?
TE-9 NVuwTWhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEj3cnZKSzVyPUCuPFc2OzJizszN M3y2e3NCVkeHUh?=
A3-KAW M3\rUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\oTWM2OD1yLkm4OFUzKM7:TR?= NXnXdItXW0GQR1XS
A101D MonsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXkdI9lUUN3ME2xMlA{ODR|IN88US=> MWfTRW5ITVJ?
OCUB-M NFnGdWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFjm[JRKSzVyPUGuNFQ1OTJizszN NVPvWZVWW0GQR1XS
ES4 M1e0ZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XQWmlEPTB;MT6wOVE1PSEQvF2= MoXiV2FPT0WU
TE-6 M{TGUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;1epFKSzVyPUGuNlEzOjZizszN M{\scnNCVkeHUh?=
D-502MG MnzKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnnNTWM2OD1zLkKzN|c3KM7:TR?= MUXTRW5ITVJ?
KNS-42 NUTLbo8{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTFwMkS0NVIh|ryP NYTVTGVFW0GQR1XS
SNU-C2B M3nCWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;GN2gyUUN3ME2xMlMxPTh7IN88US=> NUjweZA3W0GQR1XS
NCI-H1838 M1P2e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX\Ld3doUUN3ME2xMlMxPzN|IN88US=> NVfDdJhFW0GQR1XS
NKM-1 NYiyZ5BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LndmlEPTB;MT6zNFg2QSEQvF2= NXfIWFI{W0GQR1XS
GI-1 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NI\5fHdKSzVyPUGuN|YzOiEQvF2= NXyx[opjW0GQR1XS
NB5 NIDQZXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVnSTpJmUUN3ME2xMlM6QDJ5IN88US=> MXnTRW5ITVJ?
CAS-1 NG[2W5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnEc|dKSzVyPUGuOFA6QTJizszN NUC1fm9UW0GQR1XS
HCE-T NXLYb3JpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVrCXHFNUUN3ME2xMlU3PzF2IN88US=> NUnkT3lOW0GQR1XS
SBC-1 NXrjWZVCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTKTWM2OD1zLkW3PVg1KM7:TR?= MVTTRW5ITVJ?
JiyoyeP-2003 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEf1fYJKSzVyPUGuO|M1PjZizszN NYTFXotSW0GQR1XS
TE-5 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\JTWM2OD1zLke5NVM6KM7:TR?= MVnTRW5ITVJ?
CAN NVrLZWlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTFwOEKyOVIh|ryP NIHj[HVUSU6JRWK=
SK-UT-1 Mnv2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\SN4FOUUN3ME2yMlE3Pjl|IN88US=> NHOxO|NUSU6JRWK=
JVM-2 M3fqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3HId2lEPTB;Mj6zOlI5PCEQvF2= MnvVV2FPT0WU
LB771-HNC M1\ubmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\3TWM2OD1{LkW3OVUyKM7:TR?= MliyV2FPT0WU
NCCIT M2rz[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;q[GlEPTB;Mj64OlYyPiEQvF2= Ml[wV2FPT0WU
NCI-H2126 M4TvcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXwTWM2OD1{Lki3OVUzKM7:TR?= M2\lVHNCVkeHUh?=
Calu-6 NF6yXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXmzd5FRUUN3ME2zMlA2PzRzIN88US=> MYTTRW5ITVJ?
SK-LMS-1 M37JS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{j6ZWlEPTB;Mz6xNVg5PiEQvF2= Mnm4V2FPT0WU
ARH-77 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTNwNE[5NVUh|ryP NYTmNGtpW0GQR1XS
NB17 Mkj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnHUHd6UUN3ME2zMlY{QDR5IN88US=> NWH3N5d{W0GQR1XS
A253 NWf5Wm1oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVvRZpdTUUN3ME2zMlc{OjR4IN88US=> M33EWXNCVkeHUh?=
OPM-2 NV;yR|l2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1v0eWlEPTB;ND6yO|Y5PSEQvF2= MXrTRW5ITVJ?
MV-4-11 NYnPZmxDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M17OTmlEPTB;ND6zOlQ2PCEQvF2= M4TIN3NCVkeHUh?=
SR M4DXVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVSxOnByUUN3ME20MlQ6QTV2IN88US=> NFTBc4xUSU6JRWK=
KG-1 NV7hVHZGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TtdGlEPTB;ND62NFg1PSEQvF2= M{PRPHNCVkeHUh?=
OCI-AML2 M3jiU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVzJR|UxRTVwOE[xOVQh|ryP NGjBbWNUSU6JRWK=
D-247MG NFjFdm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFXzb2FKSzVyPU[uNVI2OTlizszN M3uyb3NCVkeHUh?=
DJM-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIi2V3ZKSzVyPU[uOFg2PThizszN MmrtV2FPT0WU
RPMI-6666 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTdwMkewOlch|ryP MYHTRW5ITVJ?
KARPAS-45 NU\JV2ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfjXlNKSzVyPUeuOVE3PzFizszN NV7jfJNbW0GQR1XS
LP-1 M4HydWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4HUdWlEPTB;Nz61OFc5OiEQvF2= MkW3V2FPT0WU
RS4-11 NVXESGxIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYP4NVYzUUN3ME23MlY2Pzh5IN88US=> NXrzbnczW0GQR1XS
DU-4475 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRThwMkG2OVIh|ryP NHSz[ZBUSU6JRWK=
MONO-MAC-6 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILo[JpKSzVyPUiuNlcxPjZizszN NIDsSZVUSU6JRWK=
NCI-SNU-16 MkLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3KR|BKSzVyPUiuOVYyOjhizszN M3vGb3NCVkeHUh?=
SJSA-1 NHTQXFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfzcGR{UUN3ME24MlczQDB3IN88US=> MmnuV2FPT0WU
MMAC-SF NFf1[5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWm2VWFsUUN3ME24Mlc6OzB5IN88US=> NIXyOm5USU6JRWK=
SK-NEP-1 M{D6VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRThwOEmxOVUh|ryP M{K3UHNCVkeHUh?=
J-RT3-T3-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvZWlEPTB;OD65OlUzQSEQvF2= MVrTRW5ITVJ?
SKM-1 M{\UNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUnJR|UxRTlwMEG3N|Qh|ryP M2\WWnNCVkeHUh?=
LB2241-RCC NVvPc3VVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFfBVZhKSzVyPUmuNFIxOTJizszN MkW0V2FPT0WU
SIG-M5 M3jXN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NID2TVJKSzVyPUmuNFI1QTNizszN NW\GTnl[W0GQR1XS
EVSA-T NGC2V3NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTlwMke3PVMh|ryP NWLW[FlwW0GQR1XS
GT3TKB NFjCdYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrCT21KSzVyPUmuN|U2PDZizszN M13sfHNCVkeHUh?=
NB6 M3rPdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUH0V2NVUUN3ME25MlkzOjV7IN88US=> MVnTRW5ITVJ?
EHEB NGj0SHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3TNpNKSzVyPUGwMlA3PTZizszN MVLTRW5ITVJ?
HEL NFrDNoVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDKN|RKSzVyPUGwMlQ4PzZizszN NHTTWmxUSU6JRWK=
ALL-PO M4\weGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV;ifXlsUUN3ME2xNE44QTN6IN88US=> M4jieXNCVkeHUh?=
TGW MkTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFzLkK4Nlgh|ryP NXe0OXZQW0GQR1XS
BC-3 M365TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEjSR2dKSzVyPUGyMlEyOzhizszN MnjrV2FPT0WU
IA-LM NWTt[49CT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVXUXIJQUUN3ME2xNk41PDR3IN88US=> NXfLRZlNW0GQR1XS
UACC-257 NH3wTItIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3HHN2lEPTB;MUKuPVE6QCEQvF2= NVS3U2p3W0GQR1XS
KP-N-YS NFnXPIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfSTWM2OD1zMj65Nlg{KM7:TR?= NITyNppUSU6JRWK=
Raji M3jCb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\Xc2NoUUN3ME2xN{44PDl5IN88US=> MmTuV2FPT0WU
SF539 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEPNWGtKSzVyPUGzMlg2PTdizszN MXPTRW5ITVJ?
DMS-153 NEXTU|JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTF2LkCwNlgh|ryP MX\TRW5ITVJ?
L-540 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnTLTWM2OD1zNT6wOlczKM7:TR?= MVLTRW5ITVJ?
MN-60 MkXjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjPNYpLUUN3ME2xOU4yQTd7IN88US=> M4XrV3NCVkeHUh?=
RPMI-8866 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVTJR|UxRTF5LkS0OVQh|ryP MmryV2FPT0WU
NCI-H510A NVq1fHVHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTF7LkO5O|Mh|ryP M1T3R3NCVkeHUh?=
NB13 NXPF[nBuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nFemlEPTB;MUmuOFg4PyEQvF2= NEjMN|RUSU6JRWK=
HAL-01 M4\BO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGLtUYpKSzVyPUG5Mlc2PDNizszN NXnzVnZYW0GQR1XS
NCI-H720 NIXIbXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTJyLkK3N|Mh|ryP MYXTRW5ITVJ?
REH M3X1V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWHJR|UxRTJyLk[zOVch|ryP M3LYNXNCVkeHUh?=
KNS-81-FD MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXrJR|UxRTJ|LkG0OkDPxE1? MYTTRW5ITVJ?
HC-1 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmfFTWM2OD1{ND61OVUyKM7:TR?= MmiyV2FPT0WU
NCI-H2141 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTJ2Lke3OVQh|ryP NUXlXIY1W0GQR1XS
MOLT-4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jrNWlEPTB;Mk[uOlc2OyEQvF2= M1vyVXNCVkeHUh?=
OMC-1 NF[z[WlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1f3UGlEPTB;MkeuNVQzOiEQvF2= NGWz[oFUSU6JRWK=
LC-1F NV3ncVVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jETWlEPTB;MkeuN|I1PSEQvF2= MlHIV2FPT0WU
NCI-H1304 Ml3TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoKyTWM2OD1{OD6xOlI5KM7:TR?= NVqxPJJSW0GQR1XS
BC-1 M2\Kfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTJ6Lk[1NUDPxE1? MUnTRW5ITVJ?
NCI-H64 NF7hPWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYHJR|UxRTJ7Lk[yOVMh|ryP NVHCUpVUW0GQR1XS
MOLT-16 NYHn[ZZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWjnTotZUUN3ME2yPU43Ojl{IN88US=> NVj2cXltW0GQR1XS
U-87-MG MlrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HNZWlEPTB;M{CuO|Y3KM7:TR?= M3XPeXNCVkeHUh?=
GAK NWjZW|lqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1S4TGlEPTB;M{GuNlY5PiEQvF2= Mn65V2FPT0WU
ES8 MlfOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN{LkGyOVIh|ryP NVfO[YxlW0GQR1XS
HCC1599 NGPjVFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUTCVWc2UUN3ME2zNk4{OzJ3IN88US=> Mn\hV2FPT0WU
EB-3 M1zXTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjOc3JvUUN3ME2zOE4{OTF5IN88US=> M3ezSnNCVkeHUh?=
HCC1187 MljqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnHDTWM2OD1|NT64NFUzKM7:TR?= NX\VbY06W0GQR1XS
SK-PN-DW M3;pXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MojxTWM2OD1|Nj6xPVQ{KM7:TR?= NVPY[WpGW0GQR1XS
JVM-3 NIfMUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTN5LkKzN|gh|ryP NIDtWGdUSU6JRWK=
HCC2157 NVX6R3BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX6yZlNuUUN3ME2zO{46QTR4IN88US=> MlLrV2FPT0WU
A4-Fuk NVv3[otHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{Dh[GlEPTB;M{iuNVAxQSEQvF2= NF;IUXNUSU6JRWK=
COR-L279 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7OTWM2OD12MD6yPFUyKM7:TR?= NFPwcVNUSU6JRWK=
DEL M1LLUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfwTnNKSzVyPUSxMlkxQDZizszN M4rVOHNCVkeHUh?=
NCI-H1395 NI\3cYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2WyOGlEPTB;NEKuNFE3OyEQvF2= NV7xRlQ5W0GQR1XS
MHH-NB-11 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13DbWlEPTB;NEOuNFgyQCEQvF2= MVXTRW5ITVJ?
NCI-H2107 NU\GTYN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHoSZNKSzVyPUSzMlQ5PDZizszN MnrnV2FPT0WU
NEC8 MknVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\sR49KSzVyPUS0MlM{PiEQvF2= MXPTRW5ITVJ?
COLO-684 NEXOb4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoPhTWM2OD12Nj6yNlU5KM7:TR?= M3TpXXNCVkeHUh?=
LS-411N MonmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFrUOHBKSzVyPUS4MlQ4PDhizszN NV:0WHZKW0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Dasatinib reverses splenomegaly in LMP2A/MYC double transgenic mice. Dasatinib specifically prevents colony formation by LMP2A expressing bone marrow B cells and decreased spleen size in the TgE mice. Spleen mass is significantly decreased among Dasatinib treated Tg6/λ-MYC mice when compared to the control group. Dasatinib inhibits lymphadenopathy in LMP2A/MYC double transgenic mice. Dasatinib reverses splenomegaly in Rag1KO mice engrafted with tumor cells from LMP2A/MYC double transgenic mice. Dasatinib therapy inhibits Lyn phosphorylation in B lymphocyte tumors expressing LMP2A. [3]

Protocol

Kinase Assay:

[1]

+ Expand

Kinase autophosphorylation assays:

Kinase assays using wild-type and mutant glutathione S-transferase (GST)-Abl fusion proteins (c-Abl amino acids 220-498) are done. GST-Abl fusion proteins are released from glutathione-Sepharose beads before use; the concentration of ATP is 5 μM. Immediately before use in kinase autophosphorylation and in vitro peptide substrate phosphorylation assays, GST-Abl kinase domain fusion proteins are treated with LAR tyrosine phosphatase. After 1-hour incubation at 30 °C, LAR phosphatase is inactivated by addition of sodium vanadate (1 mM). Immunoblot analysis comparing untreated GST-Abl kinase to dephosphorylated GST-Abl kinase is routinely done using phosphotyrosine-specific antibody 4G10 to confirm complete (>95%) dephosphorylation of tyrosine residues and c-Abl antibody CST 2862 to confirm equal loading of GST-Abl kinase. The Dasatinib concentration range is extended to 1,000 nM for mutant T315I. These same inhibitor concentrations are used for the in vitro peptide substrate phosphorylation assays. The three inhibitors are tested over these same concentration ranges against GST-Src kinase and GST-Lyn kinase.
Cell Research:

[1]

+ Expand
  • Cell lines: Ba/F3 cell lines
  • Concentrations: ~32 nM
  • Incubation Time: 72 hours
  • Method:

    Ba/F3 cell lines are seeded in triplicate and incubated with escalating concentrations of Dasatinib for 72 hours. Proliferation is measured using a methanethiosulfonate-based viability assay. IC50 and IC90 values are reported as the mean of three independent experiments done in quadruplicate. The inhibitor concentration ranges are 0 nM to 32 nM (Dasatinib). The Dasatinib concentration range is extended to 200 nM for mutant T315I.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: EμLMP2A (TgE and Tg6 strains), MYC (λ-MYC), and LMP2A/λ-MYC double transgenic mice (Tg6/λ-MYC)
  • Formulation: DMSO
  • Dosages: 30 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 98 mg/mL (200.81 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+5% Tween 80+ddH2O
For best results, use promptly after mixing.
5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 488.01
Formula

C22H26ClN7O2S

CAS No. 302962-49-8
Storage powder
in solvent
Synonyms BMS-354825

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03318770 Not yet recruiting Acute Lymphoblastic Leukemia Gruppo Italiano Malattie EMatologiche dell''Adulto December 2018 --
NCT03625388 Not yet recruiting Chronic Myelogenous Leukemia Hikma Pharmaceuticals LLC October 2018 Phase 2
NCT03516279 Not yet recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive|Minimal Residual Disease ECOG-ACRIN Cancer Research Group|National Cancer Institute (NCI)|Eastern Cooperative Oncology Group August 12 2018 Phase 2
NCT03595917 Recruiting B-cell Acute Lymphoblastic Leukemia|Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis|Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL Marlise R. Luskin|Novartis|Dana-Farber Cancer Institute July 24 2018 Phase 1
NCT03654768 Recruiting Chronic Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive Southwest Oncology Group|National Cancer Institute (NCI) July 20 2018 Phase 2
NCT03560908 Recruiting Relapsed AML|T(8;21)|C-KIT Mutation Institute of Hematology & Blood Diseases Hospital July 1 2018 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    what’s the difference between S1021 and S7782? Which one is better for in vivo studies?

  • Answer:

    Usually, hydrate will be more stable and dissolve better than free base. But this compound (S1021) dissolves better in DMSO than hydrate one (S7782).

  • Question 2:

    Can I give dasatinib to mice by oral gavage? If so, how to dissolve the drug?

  • Answer:

    Our S1021 Dasatinib in 1% DMSO+30% PEG 300+1% Tween 80 at 30 mg/ml is a suspension which you can administrate to mice via oral gavage. If you want a clear solution, it can be dissolved in 4% DMSO+30% PEG 300+5% Tween 80+ddH2O at 5 mg/ml clearly.

Src Signaling Pathway Map

Src Inhibitors with Unique Features

Related Src Products4

Tags: buy Dasatinib | Dasatinib supplier | purchase Dasatinib | Dasatinib cost | Dasatinib manufacturer | order Dasatinib | Dasatinib distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID